Pharmacogenetics and Genomics

Edit Your Profile

Pharmacogenetics and Genomics Journal

publication venue for

MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway. 33:1-9. 2023
Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.. 26:370-380. 2016
Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. 20:665-676. 2010
Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.. 15:769-778. 2005
Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms. 2012
Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10. 2012
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. 2011
Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis. 2011
Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. 2010
Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. 2008

International Standard Serial Number (ISSN)

1744-6872